Cosmos Health Target of Unusually Large Options Trading (NASDAQ:COSM)

Posted by Geri Gentry on Aug 20th, 2026

Cosmos Health Inc. (NASDAQ:COSM – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 2,716 call options on the company. This represents an increase of 654% compared to the average daily volume of 360 call options.

Insider Buying and Selling at Cosmos Health

In other news, CFO Georgios Terzis bought 168,135 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average price of $0.25 per share, with a total value of $42,033.75. Following the transaction, the chief financial officer directly owned 2,235,398 shares in the company, valued at approximately $558,849.50. The trade was a 8.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Grigorios Siokas purchased 349,825 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were purchased at an average price of $0.20 per share, with a total value of $69,965.00. Following the completion of the acquisition, the chief executive officer directly owned 14,597,917 shares of the company’s stock, valued at approximately $2,919,583.40. This trade represents a 2.46% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have purchased 2,204,138 shares of company stock valued at $457,137. 26.15% of the stock is owned by insiders.

Hedge Funds Weigh In On Cosmos Health

Several hedge funds and other institutional investors have recently modified their holdings of COSM. BlackRock Inc. bought a new position in shares of Cosmos Health during the second quarter valued at $49,000. Renaissance Technologies LLC increased its holdings in shares of Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after buying an additional 241,775 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after acquiring an additional 128,776 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares during the last quarter. Institutional investors own 12.61% of the company’s stock.

Cosmos Health Price Performance

Shares of COSM stock traded up $0.02 during mid-day trading on Thursday, reaching $0.21. The company’s stock had a trading volume of 1,740,404 shares, compared to its average volume of 4,458,653. The firm’s 50-day moving average is $0.22 and its two-hundred day moving average is $0.30. The company has a market cap of $12.55 million, a P/E ratio of -0.33 and a beta of 4.80. Cosmos Health has a 1-year low of $0.16 and a 1-year high of $1.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.92 and a current ratio of 1.08.

Cosmos Health (NASDAQ:COSM – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04). The business had revenue of $18.99 million during the quarter, compared to the consensus estimate of $19.42 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. On average, research analysts predict that Cosmos Health will post 0.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cosmos Health currently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on COSM

About Cosmos Health

(Get Free Report)

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.